Patients
Trials
Expanded Access
Pipeline
Zanidatamab
ZW49
Preclinical & Advanced Discovery
Partnerships
Publications
Partners
Technology
Azymetric™
ZymeLink™
EFECT™
ProTECT™
Science
Careers
Apply
Perks & Benefits
Corporate Gallery
About
Leadership
Board of Directors
News
Investors & Media
News
Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2‑Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022
May 26, 2022
Back